Abstract
Previous studies show that treatment with a polyunsaturated fatty acid, arachidonic acid (AA), or high concentrations of cycloleucine, an inhibitor of methionine adenosyltransferase (MAT), which lowers levels of S-adenosyl-L-methionine (SAM), increased toxicity in hepatocytes from pyrazole-treated rats which expressed high levels of cytochrome P450 2E1 (CYP2E1). In this study, I used concentrations of cycloleucine or AA, which by themselves do not produce any toxicity, to evaluate whether a decrease in SAM sensitizes hepatocytes to AA toxicity, especially in hepatocytes enriched in CYP2E1. Levels of SAM were lower by 50% in hepatocytes from pyrazole- compared to saline-treated rats. Cycloleucine treatment caused a 50% decline in SAM levels with both hepatocyte preparations and SAM levels were lowest in the pyrazole-treated hepatocytes. The combination of cycloleucine plus AA produced some toxicity and apoptosis in hepatocytes from saline-treated rats but increased toxicity and apoptosis was found in the hepatocytes from pyrazole-treated rats. Cytotoxicity could be prevented by incubation with SAM, the antioxidant trolox, and the mitochondrial permeability transition inhibitor trifluoperazine. The enhanced cytotoxicity could als...Continue Reading
References
Mar 1, 1991·Chemical Research in Toxicology·F P GuengerichM Iwasaki
Dec 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D F WuA I Cederbaum
Jan 1, 1990·Drug Metabolism Reviews·C S YangJ Y Hong
Jan 1, 1970·Advances in Enzyme Regulation·J B Lombardini, P Talalay
Aug 1, 1994·Alcoholism, Clinical and Experimental Research·A A NanjiA J Dannenberg
Nov 1, 1993·Alcohol·M MorimotoS W French
Jan 1, 1997·Pharmacology & Therapeutics·J M MatoM A Pajares
Jan 13, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M D WeltmanC Liddle
Mar 16, 2000·Molecular and Cellular Biochemistry·D Wu, A I Cederbaum
Jul 18, 2000·American Journal of Physiology. Gastrointestinal and Liver Physiology·S C LuH Tsukamoto
Aug 30, 2000·Proceedings of the Society for Experimental Biology and Medicine·Z GouillonS W French
Sep 8, 2000·Archives of Pharmacal Research·R F Novak, K J Woodcroft
Mar 22, 2001·Molecular Pharmacology·D Wu, A I Cederbaum
Jan 5, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jose M MatoMatias A Avila
Oct 31, 2002·The Journal of Biological Chemistry·Defeng Wu, Arthur I Cederbaum
Dec 7, 2002·The Journal of Biological Chemistry·Jingxiang Bai, Arthur I Cederbaum
Mar 13, 2003·Proceedings of the National Academy of Sciences of the United States of America·Enrique SantamariaFernando J Corrales
Mar 28, 2003·The Journal of Biological Chemistry·Maria L Martínez-ChantarMatías A Avila
Jul 9, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Heping YangShelly C Lu
Dec 18, 2004·Mutation Research·Frank J Gonzalez
Mar 15, 2005·Biochemical Pharmacology·Andres A Caro, Arthur I Cederbaum
Nov 25, 2005·American Journal of Physiology. Gastrointestinal and Liver Physiology·Defeng Wu, Arthur I Cederbaum
Dec 13, 2005·Free Radical Biology & Medicine·Jian Zhuge, Arthur I Cederbaum
Sep 12, 2006·Free Radical Biology & Medicine·Jian Zhuge, Arthur I Cederbaum
Oct 6, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Frank J Gonzalez
Apr 28, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·José M Mato, Shelly C Lu
Jul 21, 2007·Archives of Biochemistry and Biophysics·Jian Zhuge, Arthur I Cederbaum